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The a5pl integrin mediates cell adhesion  and  migra- 
tion on  fibronectin,  a  glycoprotein critical for normal 
vertebrate embryonic development. Indirect evidence 
reported to date suggests that this receptor also func- 
tions in the deposition of fibronectin  matrices. We used 
a  molecular genetic approach to critically evaluate this 
role of asp1 integrins. Mutant Chinese  hamster  ovary 
(CHO) cells deficient in a5 integrin expression  could  not 
assemble  a  fibronectin  matrix.  Reconstituting a5p1 in- 
tegrin expression by transfecting them with a full- 
length cDNA encoding the human a5 chain completely 
restored fibronectin matrix assembly. CHO cells ex- 
pressing an a5 chain lacking the cytoplasmic domain 
also assembled  a  fibronectin  matrix.  Removing the cy- 
toplasmic  domain of a5 appears to increase its activity 
in fibronectin  matrix  assembly. In addition to a5p1 inte- 
grin binding to fibronectin’s RGD-containing domain, 
cells must  bind with high affinity to fibronectin’s  amino- 
terminal  29-kDa  matrix  assembly  domain to form  a fi- 
bronectin matrix. Studies with the a5-deficient CHO 
cells show  that the expression of a5pl integrin is also 
necessary  for cells to bind  fragments containing this dis- 
tinct site in fibronectin  and  that  a  fibronectin  matrix 
increases binding of the 29-kDa  fragment.  Thus, asp1 
integrins not  only  mediate cell adhesion to fibronectin, 
but also play  an essential role in the assembly of a  fibro- 
nectin matrix.  This  role includes direct  binding to fibro- 
nectin and  modulating  a distinct binding event involv- 
ing the interaction of fibronectin’s  amino-terminal 
matrix  assembly  domain with the cell surface. 
During diverse biological processes including embryonic de- 
velopment and cytodifferentiation, wound healing,  and  tumor 
metastasis, cells must  interact  with components of the  extra- 
cellular  matrix (ECM).’ One interaction,  that of cells with  the 
adhesive glycoprotein fibronectin (FN)  has become a paradigm 
of a specific cell-ECM recognition system  mediated by cell sur- 
face receptors. The  best,characterized fibronectin  receptor is a 
member of a superfamily of transmembrane, heterodimeric 
proteins called integrins (1, 2). The  interaction of cells express- 
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ing the a5pl integrin FN receptor with FN results in aug- 
mented cell adhesion, migration,  and differentiation and  has 
been implicated in important events in early embryogenesis 
such  as  gastrulation (3). The  appearance of FN-rich matrices  is 
both  temporally and spacially regulated  during embryogenesis 
and wound healing. At least two components contribute speci- 
ficity to this important recognition system. Responsive cells 
must express a suitable receptor such as a5pl integrin. In 
addition,  the  synthesis  and  extracellular assembly of FN must 
be controlled. Unlike many  other ECM components whose as- 
sembly appears  to be entropy driven, FN does not assemble 
spontaneously in  the absence of cells (4). 
A great  deal  is known about  the  structure of FNs. They are 
hetero- and homodimeric, cell adhesive glycoproteins of ap- 
proximately 500,000 daltons consisting of two similar disulfide- 
bonded subunits  with differences created by  RNA splicing and 
by glycosylation and other post-translational modifications. 
During organogenesis, FN is a common component of the ECM 
(5) .  However, in  adult  mammals, most FN  is synthesized by the 
liver and  exists  primarily as a plasma protein present at about 
30 mg/dl in  man. Only with wounding or  during  hemostasis  is 
FN expressed locally and deposited, suggesting a highly regu- 
lated assembly process. One possibility is  that splicing variants 
absent  in hepatocytes are  the  primary source of local tissue  FN 
during embryogenesis and wound repair (6, 7). 
Structural  and cell biological studies  have  demonstrated  that 
three  sites  in  FN  are  important for FN  matrix assembly (4, 
8-16). The  first  site  is located within  the  first five type I repeats 
of FN (9) that  apparently fold to form a high  affinity  binding 
site for specific components on the surface of matrix-forming 
cells (13, 17). FN  fragments  that include this domain inhibit 
matrix formation by fibroblasts by about 90% (8,9),  resulting  in 
a specific phenotype characterized by short  stitches of cell sur- 
face FN associated with a5pl integrin receptors. This  and  re- 
lated observations suggest  this  site  participates  in fibril elon- 
gation (4, 10). This  site  has been termed  the  matrix assembly 
domain. The second site is located within a region comprised of 
the  ninth  type I and  the  first  type I11 repeats.  This  site  appears 
to mediate self-association of FN, and a specific peptide se- 
quence within  it binds to  FN (14, 15). Inhibiting  this  site re- 
duces addition of exogenous FN  to  the cell surface, but  has only 
weak effects on assembly of endogenous FN by cultured fibro- 
blasts in vitro. This  suggests  that  the homophilic interactive 
site functions in a late  stage of assembly. The  third  site  is  the 
Arg-Gly-Asp (RGDI-containing cell adhesion site  that binds to 
the a5pl integrin receptor. Antibodies to  the RGD-containing 
cell adhesive site also inhibit FN matrix assembly by fibro- 
blasts, resulting in fewer fibrils that are of normal length, 
suggesting a role for this  site  in  initiation of fibrilogenesis (8, 
10). Indeed, blocking both the integrin binding site and the 
amino-terminal  matrix assembly site  creates fibroblasts devoid 
of an  FN  matrix (10). 
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Antibodies to a5pl or to 01 integrins  that  inhibit  their func- 
tion  also inhibit  FN assembly in uitro, presumably by interfer- 
ing  with  direct binding of a5pl to FNs  RGD site  and by some- 
how inhibiting the binding of FNs  amino-terminal matrix 
assembly  domain (10, 18). Increasing  the expression of the a5 
subunit  in CHO cells by transfection also  increases  FN depo- 
sition (19). Based upon these  and  other observations, we have 
proposed a model of FN  matrix assembly in which the a5pl 
integrin  initiates or nucleates  matrix assembly, and  the  amino 
terminus is involved in fibril assembly, elongation, and insolu- 
bilization, possibly by disulfide  cross-linking into  an insoluble 
matrix (4, 8). However, this model has been controversial for 
several reasons. In  particular,  the a5pl integrin  has low avid- 
ity for FN in uitro, about 10-fold less than  the  binding of as yet 
poorly characterized cell surface components for the amino- 
terminal  matrix assembly  domain (20). Binding of the amino- 
terminal domain requires cell attachment, as suspended cells 
bind FN only via  integrin receptors (21). Moreover, recombi- 
nant fibronectins mutated  to lack the RGD cell binding  site  are 
still incorporated into  the ECM (22). These observations have 
cast doubt  upon the role and even the necessity for a5pl inte- 
grins  in  FN assembly by cells. Using a molecular  genetic  ap- 
proach, we now present conclusive evidence that a5pl inte- 
grins  participate  in  an  early  and  essential  step  in  the assembly 
of a FN  matrix. Moreover, we show that  the a5 integrin cyto- 
plasmic  domain is not  required for the receptor to  participate  in 
FN  matrix assembly. Instead,  the cytoplasmic domain  may be 
involved in negative regulation of the receptor  activity in  FN 
matrix assembly. 
EXPERIMENTAL PROCEDURES 
Materials-All organic chemicals were of analytic grade and were 
obtained from Sigma or Fisher unless otherwise specified.  Medium  for 
cell culture was from Life Technologies, Inc. Fetal bovine serum was 
from  HyClone Laboratories, Inc. (Logan, UT). FN, the 110-kDa central 
cell binding fragment and 29-kDa amino-terminal fragment were pre- 
pared as described elsewhere (8, 23). 
Cell Lines and Cell  Culture-CHO  wild-type  cells  were  grown and 
maintained as previously  described (24). Cells were  grown as monolay- 
ers in a-MEM supplemented with 10% heat-inactivated fetal bovine 
serum  and  2 mM glutamine and routinely passaged with trypsin-EDTA. 
In some experiments, fetal bovine serum was replaced with FN-free 
fetal bovine serum, and the medium was supplemented with 50 pg/ml 
bovine plasma FN or 50 pg/ml human plasma FN as specified. The CHO 
a5pl integrin-deficient variants (CHO B2 and 1-23)  were selected from 
the CHO wild-type  cells by fluorescent-activated cell sorting using anti- 
a5pl integrin antibodies and cloning (24). The CHO B2 cells express 
essentially no a5 subunit  and were used as representative of the  a5pl 
integrin-deficient phenotype (see Table I). CHO 1-23 expresses about 
1520% of the level of a5 expressed by the parent cell line (Table I) and 
was used as a control  for  cell expressing similar levels of the a5 subunit 
with a cytoplasmic  domain truncation (see below). The CHO  B2B4  cell 
line expresses a full length human a5 integrin chain. This line was 
obtained by transfecting with a  human a5 expression vector  (pECE-aB), 
selection, and screening by  ELISA and flow cytometry (25). The CHO 
BWal was obtained by transfecting CHO B2 cells with the plasmid 
pECE-a5/l which contains the human a5 integrin cDNA sequence en- 
coding the extracellular domain, transmembrane domain and the first 
2 amino acid residues of the cytoplasmic domain.2 CHO  B2B4 and CHO 
BWal  cells  were  grown a d maintained similarly to CHO wild-type  cells 
except that the culture medium was supplemented with 200 pg/ml 
geneticin. The characteristics of the cell lines studied are outlined in 
Table I. 
Immunofluorescence-Cells were plated in Lab-Tek 8-chamber cul- 
ture slides (Nunc, Inc., Naperville, IL) in media containing 50 pg/ml 
bovine plasma FN at densities yielding confluent  monolayers after  3 
days. Cells were fixed with ethanol and stained with a rabbit anti- 
fibronectin antibody and fluorescein isothiocyanate-conjugated goat 
anti-rabbit IgG antibodies as previously  described (8,lO). The cells were 
Juliano, R. L. (1993) J. Cell  Biol. 122, 209-211. 
Bauer, J. S., Varner, J., Schreiner, C.,  Kornberg, L., Nichols, R., and 
observed under epifluorescence and differential interference contrast 
microscopy. 
Determination of Fibronectin and Entactin Deposition by Immuno- 
blotting-CHO cells were cultured in medium supplemented with 50 
pg/ml bovine plasma FN as described above or FN-free medium in 
which fetal bovine serum was replaced by FN-depleted fetal bovine 
serum. Confluent cell layers were washed with phosphate-buffered sa- 
line and extracted with 3%  Triton  X-100 and 2% deoxycholate sequen- 
tially to  isolate the disulfide cross-linked, detergent-insoluble ECM 
fraction (9). The material insoluble in 2%  deoxycholate  was  solubilized 
in SDS and separated by SDS-polyacrylamide  gel electrophoresis under 
reducing conditions. FN and entactin were detected using a rabbit 
anti-FN antibody or a rabbit anti-entactin antibody,  respectively, and 
alkaline phosphatase-conjugated goat-anti-rabbit IgG (Kirkegaard & 
Perry Laboratories, Gaithersburg, MD) after  transfer to a poly(viny1- 
idene fluoride) membrane (Immobilon-PR, Millipore  Corp.). Each lane 
was loaded with the matrix fraction corresponding to 200  pg  of the 3% 
Triton  X-100-soluble cellular proteins as determined by a Bio-Rad  pro- 
tein assay (Bio-Rad). 
Quantification of Fibronectin Matrix Assembly-CHO cells were cul- 
tured in medium supplemented with 10% FN-free fetal bovine serum 
and 50 pg/ml human plasma FN in 100-mm tissue culture plates. The 
cells  were harvested with a cell scraper after  2 days. Protein present in 
a 3% Triton X-100 lysate was measured using the Bio-Rad protein 
assay. The deoxycholate-insoluble fraction was isolated, solubilized, re- 
duced, and carboxymethylated as described  previously (9). The FN in 
the deoxycholate-insoluble fraction was quantified using a capture 
ELISA assay specific for human FN (9). In brief, polystyrene ELISA 
plates (Corning, Inc., Corning, N Y )  were coated with 5 pg/ml anti- 
human fibronectin mouse  monoclonal antibody N294, and the remain- 
ing protein binding sites were blocked with 5 mg/ml bovine serum 
albumin in 100 mM NaHC03 (pH 9.2) containing 0.05% Tween-200. The 
plates were rinsed twice with 2 mg/ml  bovine serum albumin in 50 mM 
Tris-HC1,200 mM NaCI,  0.2%  Triton  X-100, pH  7.4, at room temperature 
(washing buffer), and twice with 0.2%  SDS, 1% Triton X-100 in 50 m~ 
Tris-HCI, 5 mM EDTA,  180 mM NaCl, pH 7.4, at room temperature. The 
solubilized  FN was captured by immunoadsorption to the N294-coated 
plates. Between steps, assay plates were washed four times with wash- 
ing buffer.  Bound  FN was detected by incubation with 2 pg/ml rabbit 
anti-fibronectin IgG fraction followed  by incubation with 0.5  pg/ml al- 
kaline phosphatase-conjugated anti-rabbit antibody (Kirkegaard & 
Perry Laboratories). After rinsing five times with washing buffer,  bound 
alkaline phosphatase conjugate was detected colorimetrically with p -  
nitrophenyl phosphate at 405  nm on a V, kinetic microplate reader 
and analyzed using SOFTmax analysis software (Molecular Devices 
Inc.,  Menlo Park, CA). The data from measurements of FN amount and 
cellular protein amount were analyzed using an analysis of covariance 
(26). This statistical analysis tests for a  linear relationship between 
detergent insoluble matrix FN and  total cellular protein. The analysis 
indicated that  the increases of the ECM FN amount in relation to the 
amount of cellular protein were highest for  CHO  B2B4 cells ( p  < 0.01). 
Line fits by linear regression were drawn through the  data. 
Binding of FNs Amino-terminal 29-kDa Fragment to Cell Layers 
-CHO cells  were seeded in a-MEM supplemented with 2 mM glutamine 
and 10% heat-inactivated fetal bovine serum depleted of FN  or contain- 
ing 50 pg/ml  bovine plasma FN as specified, in 96-well tissue culture 
plates a t  densities which  yielded confluent monolayers after 2 days. The 
binding of the amino-terminal 29-kDa fragment to  the confluent cell 
monolayers was measured as previously  described (9) using a 1-h incu- 
bation period. The binding medium (100 p1) contained 8 pg/ml(275 nM) 
1261-labeled 29-kDa FN fragment (specific activity 8 x lo5 cpdpg), 2 
mg/ml BSA, and 10 mM HEPES in a-MEM. Nonspecific binding was 
determined by adding a 100-fold  excess of unlabeled 29-kDa fragment 
and ranged between 0.15 and 0.25  ng/well. 
Binding ofFN 110-kDa Central Cell Binding Fragment to  Cell  Layers 
"CHO cells  were seeded in a-MEM supplemented with 2 mM glutamine 
and 10% FN- depleted heat-inactivated fetal bovine serum in 24-well 
tissue culture plates at densities which  yielded confluent monolayers 
after 2 days. Confluent cell  monolayers were rinsed twice with 10 mg/ml 
bovine serum albumin, 10 mM HEPES in a-MEM medium (binding 
medium). The cells  were then incubated with the binding medium con- 
taining 33 pg/ml(300 nM) human plasma 110-kDa FNs major  cell  bind- 
ing fragment at 4 "C  for 45  min. At the end of the incubation, cells in 
each  well  were rinsed five times with a-MEM  medium supplemented 
with 10 mM HEPES and lysed with 0.3 ml of 1% Triton X-100, 180 nM 
NaC1,5 mM EDTA, and protease inhibitors (2 mM phenylmethylsulfonyl 
fluoride, 0.2 mM 4-[2-aminoethyl]-benzenesulfonyl f uoride HCI 1 pg/ml 
aprotinin, 1 mM benzamidine, 10 pg/ml leupeptin, 10 pg/ml pepstatin)  in 
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50 mM Tris-HC1, pH 7.4. The amount of human plasma FN 110-kDa 
fragment in the cell lysate (bound) was determined using the human 
FN-specific  capture ELISA as described  above. 
RESULTS 
a5pl Zntegrin Functions  in an Early and Essential  Step in 
Fibronectin Matrix Assembly-The parental wild-type CHO 
cell line we used (24, 25) assembles exogenously supplied FN 
into a fibrillar matrix typical of that deposited by fibroblastic 
cells in vitro and  in vivo (Fig. 1, A and B ) .  The a5pl integrin- 
deficient variant cell line (CHO B2) was incapable of assem- 
bling a  fibrillar  FN  matrix (Fig. 1, C and D). The inability of the 
a5pl integrin-deficient CHO B2 cells to assemble FN could 
result from other genetic alterations, e.g. absence of putative 
receptors binding to FNs amino-terminal matrix assembly do- 
main. To address this possibility,  we tested  whether reversion 
of the  a5pl integrin-deficient phenotype would restore  FN ma- 
trix assembly ability. An a5-positive cell line, designated CHO 
B2B4, was obtained by transfecting the CHO  B2 cells with a 
plasmid containing a full-length cDNA for the  human a5 inte- 
grin, flow cytometry, and cloning (24). B2B4 expresses slightly 
greater amounts of a5pl on the cell surface than  the  parental 
CHO wild-type cells based on  ELISA (Table I).  The expression 
of the  human  a5hamster p l  chimeric FN receptor in CHO  B2 
cells restores the ability of these cells to assemble a  FN matrix 
(Fig. 1, E and F). 
Diploid fibroblasts characteristically deposit FN  into a ma- 
trix form that resists solubilization in deoxycholate containing 
solutions (4, 9). Accordingly,  we extracted cell layers  with the 
detergent, solubilized the deoxycholate insoluble fraction with 
SDS and dithiothreitol, and used immunoblotting to analyze 
the FN  content of the solubilized ECM fraction. The results  are 
shown in Fig. 2. The parental line expressing a5pl and  the cell 
line expressing human  a5hamster p l  incorporated exog- 
enously supplied FN into the deoxycholate-insoluble ECM, 
whereas  FN  was not detected in the matrix isolated from the 
a5-deficient CHO  B2  cells (Fig. 2). The inability to deposit FN 
was not a general defect, as entactin, another ECM protein, 
was  present in similar quantities in the deoxycholate-insoluble 
ECM isolated from both the wild-type CHO  cells and  the a5- 
deficient CHO variant (Fig. 2). 
Role of a5pl Integrin Cytoplasmic Domain in FN Matrix 
Assembly-Previous studies  indicate that  the activity of cells to 
assemble a FN matrix may be regulated  through  intracellular 
signaling systems. For example, treating human skin fibro- 
blasts  with  agents  increasing  intracellular CAMP reduces FN 
deposition in  the ECM (27). Similarly, when F9 teratocarci- 
noma cells are exposed to retinoic acid, a5pl integrins are 
dephosphorylated, and  the cells gain the ability to assemble a 
FN  matrix (28). Intracellular injection of antibodies to the cy- 
toplasmic domain of integrin p l  subunit inhibits FN-fibril for- 
mation in  amphibian embryos (29). These studies  suggest that 
integrin a or p cytoplasmic domains may function in  regulating 
integrin activity or signal transduction. It seems clear that  the 
p l  subunit cytoplasmic domain is required to localize integrin 
receptors to adhesion sites, whereas the a5 subunit cytoplasmic 
domain is not required (30). 
To investigate the role of the  a5 cytoplasmic domain in FN 
matrix assembly, a5-deficient CHO  B2  cells were transfected 
with the plasmid pECE-a5/1 which contains the human a5 
integrin cDNA sequence encoding the extracellular domain, 
transmembrane domain, and  the first 2 amino acid residues 
of the cytoplasmic domain.2 Human a5 carboxyl-terminal 
sequence is LLMLYKLGFFKRSLPYGTAMEKAQLKPPAT- 
SDA,049; pECE-a5/1 carboxyl-terminal sequence is LLI- 
A  stable cell line (CHO B2/al) expressing the  truncated a5 
~L'l023. 
FIG. 1. CHO cells expressing aSf31 integrins with or without  an 
a6 cytoplasmic domain organize a Fh' matrix, whereas a5pl 
deficient  cells do not. CHO wild-type (A, B ) ,  a5 deficient B2 (C, D), 
B2B4 expressing the human a5 subunit (E, F), BWal cells expressing 
the human a5 subunit with a  truncated  cytoplasmic  domain ( G ,  H )  and 
1-23 cells ( I ,  J) were  cultured in the presence of  FN  and stained with  a 
rabbit  anti-fibronectin  antibody  (IgG  fraction)  and  fluorescein  isothio- 
cyanate-conjugated goat anti-rabbit IgG antibodies as described  under 
"Experimental  Procedures."  The cells were  observed  under epifluores- 
cence (left p a d s )  or differential  interference  contrast (right panels) 
microscopy.  The scale bar in H equals 200 pm  and applies to all panels. 
integrin subunit was isolated by  flow cytometry. The resulting 
cells, designated CHO  B2/a1, expressed about 1520% of pa- 
rental a5pl integrin levels as estimated by  flow cytometry and 
ELISA (Table I). To confirm the absence of the  human  a5 cyto- 
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TABLE I 
Relative cell surface a5pl integrin expression levels of CHO clones 
The cell surface expression levels of a5pl  integrin were estimated by 
ELISA using  anti-a5pl integrin antibodies as described previously (24, 
25). Results were normalized using  the  levels of a5pl  integrin expres- 
sion on CHO wild-type cells as 100. 















FIG. 2. CHO cells expressing asp1 integrins  deposit  a FN ma- 
trix resisting  detergent  solubilization,  whereas a5pl deficient 
cells do  not. CHO wild-type, B2, B2B4, B2/al, and 1-23 cells were 
grown either in medium supplemented with 50 pg/ml bovine plasma FN 
(Cultured  with FN) or FN-free medium in which fetal bovine serum was 
replaced by FN-depleted fetal bovine serum and no FN was added to the 
medium (left  lane,  CHO Wild Type). The deoxycholate-insoluble ECM 
fraction was detected by immunoblot as described under “Experimental 
Procedures.” Each lane was loaded with  the matrix fraction correspond- 
ing to 200 pg of the 3% Triton X-100-soluble cellular proteins as deter- 
mined by the Bradford dye assay. 
plasmic domain, we stained  them  with  the monoclonal anti- 
body human VIF4 recognizing the  extracellular domain of the 
human a5 integrin  chain (31) or the  synthetic peptide  antibody 
Ab33 to  the a5 cytoplasmic domain (10). The cells stained  with 
VIF4 but  not  with Ab33, confirming that  the a5 integrin  chains 
expressed by these cells lacked the cytoplasmic domain (data 
not shown). 
Similar to the  parental line, the CHO B2/al cells also as- 
sembled FN  into a pericellular matrix (Fig. 1, G and H).  It was 
important to compare their  ability to assemble a FN  matrix 
with  that of another cell line  expressing  similar levels of a5pl 
integrin  with an  intact cytoplasmic domain. Accordingly, we 
utilized the  line CHO 1-23. Immunoblot assay  indicates  that 
the CHO B2/al cells incorporated  more FN  into  the deoxycho- 
late-insoluble matrix  than did the CHO cells expressing  similar 
levels of normal  hamster a5pl integrin (compare lane B2/al 
with  lane 1-23 in Fig. 2). This is supported by the  result of 
immunofluorescent staining of these two cell lines (compare G 
with H in Fig. 1). To confirm this, we measured  the  human 
plasma  FN incorporated into  the CHO B2B4, 1-23, and  B2/al 
extracellular  matrices  using a quantitive  capture ELISA. FN 
matrix assembly depends upon cell density  and  other factors, 
including the concentration of extracellular FN. We controlled 
the latter by adding  the  same concentration of exogenous FN  to 
each culture. To correct for cell density, we measured both FN 
matrix  and  the 3% Triton-X 100-soluble cellular  proteins from 
the  same  culture. The relationships between them  are shown in 
Fig. 3. The  amount of FN deposited into  the ECM increased 
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3% Triton X.100 soluble cellular proteins (mg) 
domain truncation deposit more FW into the ECM than CHO 
FIG. 3. CHO cells expressing a5 integrin with a cytoplasmic 
cells expressing similar level of full-length a5 integrin. CHO 
B2B4, 1-23, and BWal cells were cultured in a-MEM medium supple- 
mented with 10% FN-free fetal bovine serum, 50 pg/ml human plasma 
FN, and 200 pg/ml geneticin (B2B4 and BWal) in 100-mm tissue cul- 
ture plates for 2 days. The extracellular matrices were isolated, and 
human plasma FN in the matrices was quantified using capture ELISA 
as described under “Experimental Procedures.” The data presented are 
from at least four separate experiments with an overall mean * S.E. of 
3% Triton X-100-soluble cellular protein = 2.3 + 0.1 mg. Each experi- 
ment consisted of at least duplicate samples from each cell line. The 
bars indicate the standard deviation of the mean, and the lines repre- 
sent linear regression analysis. 
with  increasing cell density  in all three cell lines.  Interestingly, 
the  FN accumulation in B2B4 cells (Fig. 3 A )  increases to a 
greater  extent  with  increasing cell density  than it does in 1-23 
(Fig. 3B)  and  B2/al (Fig. 3C) cells. This  increase  in accumula- 
tion  is  similar  to  the difference of the cell surface a5 expression 
levels between the cell lines (Table I), a result suggesting that 
increasing integrin density increases the rate of FN matrix 
assembly. Moreover, on average, the CHO B2/al cell line ex- 
pressing a5 integrin  with a truncated cytoplasmic domain de- 
posits  more than twice the  amount of FN  into  the ECM  com- 
pared to CHO 1-23 cells, which express a similar level of full- 
length a5 on their surface.  At an  average confluent cell density 
which is  equal  to a mean soluble cellular protein  content of 2.3 
mg per 100-mm dish,  approximately 11, 4, and 9 ng of deoxy- 
cholate-insoluble FN were  deposited by B2B4, 1-23, and BWal 
cells, respectively. Thus,  the cytoplasmic domain of the a5 sub- 
unit is not  required for the receptor to participate  in FN matrix 
assembly. Moreover, removing the cytoplasmic domain of a5 
appears  to  increase  its activity in  FN  matrix assembly. I t  was 
important to ensure  that  this observation was  not  due  to  inad- 
vertent clonal selection of a cell line  particularly efficient at FN 
matrix assembly. Accordingly, we isolated an additional CHO 
cell line  (HH3) from pECE-a5/1  transfected CHO  B2 cells by 
fluorescence-activated cell sorting. Although HH3 cells express 
approximately 50% less a5 subunit on their surface than CHO 
wild-type cells, they deposit  approximately 50% more 2% de- 
oxycholate-insoluble FN  matrix  than  the wild-type cells as de- 
termined by capture ELISA. Therefore, it appears  that CHO 
cells expressing a5 subunits  with  the cytoplasmic domain trun- 
cated deposit  more FN  than  the cells expressing  the full-length 
a5. This  suggests  that  the cytoplasmic domain  may somehow 
decrease  FN  matrix assembly activity. 
Binding of FWs Amino-terminal Matrix Assembly Domain to 
CHO Cells Is Modulated by Both the Cell Surface Level of asp1 
Zntegrin and the Presence of an FN Matrix-Cells that as- 
semble a FN  matrix bind FNs  29-kDa amino-terminal matrix 
assembly  domain with  high avidity (9). This binding is a critical 
step  in  the  FN  matrix assembly process, as inhibiting  it with 
amino-terminal  fragments or with antibodies to  this domain 
decreases  FN deposition by about 90% (8). The  remaining FN is 
found in  short  stitches on the cell surface co-distributed with 
a5p1 integrins.  Integrins of the 01 class appear to modulate 
this process, as antibodies to p l  or to a5pl  inhibiting cell ad- 
hesion  also inhibit binding of FNs 70-kDa amino-terminal do- 
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domain is modulated by  both the cell surface expression level of 
FIG. 4. Binding of the 29-kDa  amino-terminal  matrix assembly 
u6pl integrin and the presence of a FN matrix. Binding of the 
29-kDa amino-terminal  fragment ( A )  and 110-kDa central cell binding 
fragment ( B )  to CHO B2, 1-23, B a a l ,  and B2B4 cells was  determined 
as  described under “Experimental  Procedures.”  Each bur represents  the 
mean * S.E. of three replicates of the lZ5I-labeled 29-kDa fragment (A) 
or 110-kDa fragment ( B )  bound to CHO cells grown in  the absence of 
exogenously supplied FN  or  in  the presence of 50 pg/ml bovine plasma 
FN as indicated in  the figure. 
main (11) and  the 29-kDa d ~ m a i n . ~  We used the high level a5 
expressor B2B4, the low level full length a5 expressor 1-23, the 
low level cytoplasmic domain truncated a5 expressor B2/al, 
and  the a5-deficient cell line B2 to  investigate  the role of a5p l  
integrins  in  this  FN  binding  event (Fig. 4A). These cell lines, 
together with the ability to manipulate the pericellular FN 
matrix by supplying exogenous FN, allowed us  to probe the role 
of a5pl and  FN in the 29-kDa fragment binding. Binding of the 
29-kDa fragment  is  dependent on both the expression level of 
a5pl and  the presence of a extracellular  FN  matrix. CHO cells 
deposit no FN  matrix  in  the absence of exogenously supplied 
FN (Fig. 2, left lane). In  the absence of a FN  matrix, very low 
levels of the 29-kDa fragment binding  were found for all four 
cell lines. However, if the cells were grown in  the presence of 
exogenously supplied  FN allowing a FN  matrix  to form, much 
greater 29-kDa fragment  binding activity was  seen  in  the  three 
a5-expressing cell lines. This  was especially noticeable in  the 
high level a5 expressor B2B4. The  increase  in 29-kDa binding 
activity  was proportional to  the expression of a5pl integrin, 
suggesting  that  the a5pl integrin,  together  with a FN  matrix, 
somehow modulates  the  interaction of FNs  amino-terminal do- 
main  with  the cell surface. 
We also studied  the  binding of  FN’s RGD-containing 110-kDa 
central cell binding fragment. As expected from the level of a5 
expression (Table I), CHO B2B4 cells exhibit much greater 
A. H. Limper and J. A. McDonald, unpublished results. 
binding of the 110-kDa fragment  than do B2 cells (Fig. 4B). 
Therefore, although  the a5pl integrin  participates  in both the 
cell-FNs  central cell binding  domain and  the cell-FN’s amino- 
terminal domain interactions, dissimilar mechanisms exist. 
The a5pl  integrin  mediates  the 110-kDa fragment binding  di- 
rectly, while the 29-kDa fragment binding is  greatly enhanced 
by the presence of a pericellular FN  matrix. Finally, the fact 
that  similar levels of the 29-kDa binding activities were ob- 
served in both B2/al  and  1-23 cells (Fig. 4A) suggests  that  the 
a5 cytoplasmic domain is  not required for the binding of FNs 
amino-terminal domain to  the cell surface. 
DISCUSSION 
Several conclusions can be drawn from our work. First,  the 
hybrid human  a5hamster 01 integrin complex functions in  FN 
matrix assembly, just as it does in cell adhesion and migration 
(25). Accordingly, the molecular determinants  mediating sub- 
unit assembly and formation of functional domains are con- 
served  between hamster  and  human a5 subunits. Second, the 
a5pl integrin functions in  an  early  and  essential  step  in fibro- 
nectin matrix assembly  since the a5-deficient CHO B2 cells are 
completely devoid of FN fibrils  (Fig. 1, C and D). Restoring a5 
expression by transfection provides formal proof that  the fail- 
ure of the u5-deficient CHO B2 cells to assemble a FN  matrix 
is  due  to  the lack of expression of the a501 integrin,  rather  than 
the absence of some other molecule. These results  demonstrate 
definitively that  in  this cell line a5pl integrin  participates in 
FN  matrix assembly and  that  it functions in  the  earliest de- 
tectible stages of matrix assembly as previously hypothesized 
(8, 10). We cannot exclude the  direct or indirect participation of 
other  integrins in the process of FN  matrix assembly, nor  can 
we conclude that  other  integrins  cannot  substitute for a5pl. 
For  example, the CHO cells utilize an  adhesive pathway inde- 
pendent of a5pl on the  serum coated substrate,  and cell at- 
tachment  is required for matrix assembly. Similarly, other  FN 
binding  integrins including a3p1 and mol may be capable of 
substituting for a5pl. However, recent studies suggest that 
over expression of FN binding integrin  avp1  in CHO B2 cells 
promoted adhesion to FN, yet  cannot  substitute for a5 in FN 
matrix assembly  (32).  Therefore, the role of the  a5pl integrin 
in  FN  matrix assembly is probably not limited to binding of FN. 
Although the a5pl integrin functions in  FN  matrix assembly, 
its cytoplasmic domain is not required. Indeed, our studies 
suggest  that  truncation of the a5 cytoplasmic domain  may ac- 
tually  enhance  matrix assembly. Thus,  the a5  cytoplasmic do- 
main may serve some regulatory function. This regulation 
could be achieved by either  interaction of the cytoplasmic do- 
main  with  intracellular molecules or by covalent modification 
such as phosphorylation of the cytoplasmic domain of the  re- 
ceptor. Although more studies  are necessary to firmly establish 
such a regulatory role for the a5 integrin cytoplasmic domain  in 
FN  matrix assembly, truncating  the cytoplasmic domain of the 
a subunit of the  integrin aII,,pB increased its ligand binding 
affinity, demonstrating modulation by integrin a subunit cyto- 
plasmic  domains  (33). Studies  with chimeric integrins  are also 
compatible with a regulatory function for the (Y subunit cyto- 
plasmic  domains (34). 
The participation of a5pl in 29-kDa fragment binding is 
confirmed by this study. The binding of the 29-kDa fragment  to 
cells is  apparently  not  due  to a direct  ligand-receptor interac- 
tion, as detergent-solubilized a5p1 does not bind to the 29-kDa 
fragment3  nor  to  the  larger ‘IO-kDa amino-terminal  fragment 
(11). Surprisingly, FN binding to a5pl  is also not  required, at 
least once a FN  matrix  is  established, as inhibiting  a5Pl-FN 
binding with monoclonal antibodies to FNs RGD-containing 
cell adhesive site does not  inhibit  the 29-kDa fragment binding 
21888 a5pl Role in Fibronectin Matrix  Assembly 
to the cell ~ur face .~  However, the presence of a preexisting FN 
matrix appears to greatly enhance the cell-FNs amino-termi- 
nal domain interaction. This suggests that  the  a5pl integrin 
complex, together with a FN matrix, somehow modulates the 
interaction of FNs amino-terminal domain with the cell sur- 
face. This result also supports the notion that  the cell-FNs 
amino-terminal domain interaction is involved in FN fibril 
elongation whereas the  a5pl integrin-FNs  central cell binding 
domain interaction is crucial for initiation of the FN matrix 
assembly. 
Finally, although a5pl integrin expression is necessary, it is 
apparently not sufficient for matrix assembly. Certain cells, 
such as macrophages, synthesize FN and possess a5pl recep- 
tors, but are incapable of FN matrix assembly (35, 36). The 
human colon carcinoma cell line HT29, which normally ex- 
presses pl ,  a2, a3, (w6, and av  but not a5 (371, does not assemble 
a FN mat rk4  Expression of a5 in HT29  cells by transfection 
with an a5 expression vector enable the cells to adhere to FN5 
but not to assemble an FN m a t r i ~ . ~  
The a5pl-deficient cell line CHO  B2 is  a particularly useful 
tool to explore these remaining questions. Unlike many cell 
lines, it does not synthesize significant quantities of endog- 
enous FN but is potentially capable of assembling a FN matrix. 
This should allow us to dissect the process of FN matrix  as- 
sembly and test for the requirements of various sites of FN 
(such as the RGD cell binding site)  and  its  integrin receptors in 
different steps of FN matrix assembly. 
Mechanistically,  FN matrix assembly is  a complex  process in 
which  low affinity a5pl integrin receptors modulate the activ- 
ity of a higher avidity binding system that is required for  depo- 
sition of a FN matrix. Cells possessing a5pl integrins but lack- 
ing  other  essential component(s) of the matrix assembly system 
adhere  and respond to FN matrices. However, in cells capable 
of assembling a FN matrix, a5pl integrins  initiate  a distinct, 
high affinity binding event resulting in FN fibrilogenesis. 
These initial  steps are likely followed  by further FN  deposition 
by homophilic FN-FN interactions mediated at yet a  third  site 
(14, 15). 
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